+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

ELISpot and FluoroSpot Assay Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

  • PDF Icon


  • 111 Pages
  • August 2022
  • Region: Global
  • Mordor Intelligence
  • ID: 4896097
UP TO OFF until Dec 31st 2023
The ELISpot and FluoroSpot Assay Market is expected to grow at a CAGR of more than 13.3% globally during the forecast period (2022-2027).

The COVID-19 pandemic has affected the healthcare systems globally and also has had a significant impact on the ELISpot and FluoroSpot assay market. According to the article by Medtech published in 2020, there seems to be a link between antibody titers and T-cell responsiveness in COVID-19. The strongest T cell response was observed as the highest number of IFN-/IL-2 secreting cells in a FluoroSpot assay in three individuals (C4, C5, and C7) with the lowest antibody response in COVID-19 patients. Thus, to check the SARS-CoV-2-specific T- and B-cell immunity, the elispot and flurospot are used in COVID-19 patients.

The major factors attributing to the growth of the ELISpot and FluoroSpot assay market are the rising vaccine research to tackle the drug-resistant strains challenge, the growing global occurrence of chronic illnesses, and technological innovations in ELISpot and FluoroSpot analyzers and assay kits which are assessed to upsurge the market growth for ELISpot and FluoroSpot assay. According to the Globocan 2020 fact sheet, an estimated 19,292,789 new cancer cases were diagnosed worldwide, with nearly 9,958,133 deaths due to cancers globally. Additionally, according to estimates from the International Agency for Research on Cancer (IARC), by 2040, the global burden of cancers is expected to grow to 27.5 million new cancer cases and 16.3 million deaths worldwide. The increasing incidence of cancer cases is expected to drive the need for elispot and flurospot assay markets. In addition, according to an April 2021 update by the World Health Organization (WHO), non-communicable diseases (NCDs) kill 41 million people each year, equivalent to 71% of all deaths globally, and each year, more than 15 million people die from an NCD between the ages of 30 and 69 years; 85% of these "premature" deaths occur in low- and middle-income countries. Thus increasing the prevalence of chronic diseases to boost the market study.

ELISpot is a crucial path to vaccine development for many illnesses, namely AIDS, tuberculosis, HIV, malaria, cancer, and flu. The ELISpot test is among the most widely utilized immunoassays in clinical studies to assess vaccines. This reputation was based mainly on the higher sensitivity of the sample, statistical read-out, and ease of use in both large screening and individual tests. The test can be used to assess both T-cell reactions and vaccine-specific antibody-producing B cells.

Thus, given the aforementioned factors, the cancer therapy market is expected to witness tremendous growth over the forecast period.

Key Market Trends

Assay Kits is Expected to Hold the Largest Market Share in the ELISpot and FluoroSpot Assay Market

Assay kits are employed in a wide range of applications in life science research, drug development, and environmental monitoring, including researching disease pathways, screening for prospective drug candidates, and evaluating biopharmaceutical production processes.

Dominant share is retained by the assay kits segment owing to the factors such as a high incidence of chronic ailments and increased use of these products for vaccine development in clinical studies.

As per the (WHO) World Health Organization December 2020, the main chronic illnesses presently make up nearly 60% of all fatalities and 43% of the worldwide disease burden. Their contribution is projected to increase up to 73% of all fatalities by 2020 and 60% of the worldwide morbidity. In addition, in developing countries, 79% of the deaths take place owing to chronic diseases. Furthermore, the technological innovation of assay kits and analyzers for ELISpot and FluoroSpot is also expected to drive market growth.

North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall ELISpot and FluoroSpot assay market throughout the forecast period. This is owing to factors such as the rising prevalence of chronic disorders such as infectious diseases and the geriatric population.

According to the Globocan 2020 report, an estimated 2,281,658 new cancer cases will be diagnosed in the United States in 2020. In 2020, The most common cancers were breast (253,465), lung (227,875), prostate (209,512), and colon (101,809) in the United States. The United States has one of the highest prevalences of some chronic diseases, such as cancer and cardiovascular diseases, as compared to other developed countries, which may have a significant impact on the growth of the studied market in the country.​

Furthermore, according to the Center for Disease Control and Prevention 2021, in the United States, chronic diseases such as heart disease, cancer, and diabetes are the main causes of mortality and disability. They are also the main drivers of the USD3.8 trillion in annual healthcare spending in the United States. Thus rising prevalence of chronic diseases and growing healthcare spending boost the market in the country over the forecast period.

Competitive Landscape

The ELISpot and FluoroSpot assay market is moderately competitive and consists of a few major players. In terms of market share, few of the major players are currently dominating the market. And some prominent players are vigorously making acquisitions and new product launches with the other companies to consolidate their market positions across the globe.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.

Table of Contents

1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Incidence of Chronic Diseases
4.2.2 Technological Breakthroughs in Test Kits and analyzers for ELISpot and FluoroSpot
4.3 Market Restraints
4.3.1 Availability of alternative detection technologies
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Product
5.1.1 Analyzers
5.1.2 Assay kits
5.1.3 Ancillary Products
5.2 By End User
5.2.1 Hospitals & Clinical labs
5.2.2 Biopharmaceutical Company
5.2.3 Research Institutes
5.3 By Application
5.3.1 Research Vaccine Development Clinical Trials Cancer Research
5.3.2 Diagnostics Infectious Disease Transplants
5.4 Geography
5.4.1 North America United States Canada Mexico
5.4.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.4.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.4.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.4.5 South America Brazil Argentina Rest of South America
6.1 Company Profiles
6.1.1 Becton, Dickinson and Company
6.1.2 U-Cytech Biosciences
6.1.3 Cellular Technologies Limited
6.1.4 Mabtech AB
6.1.5 Abcam
6.1.6 Autoimmun Diagnostika GmbH
6.1.7 Lophius Biosciences GmbH
6.1.8 Bio-Connect B.V.
6.1.9 Oxford Immunotec
6.1.10 Bio-Techne Corporation

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Becton, Dickinson and Company
  • U-Cytech Biosciences
  • Cellular Technologies Limited
  • Mabtech AB
  • Abcam
  • Autoimmun Diagnostika GmbH
  • Lophius Biosciences GmbH
  • Bio-Connect B.V.
  • Oxford Immunotec
  • Bio-Techne Corporation